- Pharmaceutics International, Inc. (Pii) has invested $3.6 million in advanced labeling, fill/finish, and automated visual inspection technologies to expand its prefilled syringe (PFS) capabilities.
- The investment includes the installation of an Optima syringe labeler and Antares automated visual inspection system, with full operational use expected by mid-2025.
Pharmaceutics International Inc. (Pii), a contract development and manufacturing organization (CDMO), has announced a $3.6 million investment to enhance its prefilled syringe (PFS) capabilities. This move is aimed at improving efficiency and regulatory compliance for pharmaceutical and biotech companies in the production of injectable medicines.
The investment includes the addition of two advanced technologies: an Optima syringe labeler and an Antares automated visual inspection (AVI) system. These upgrades will streamline Pii’s fill/finish and labeling services, enabling the company to provide integrated solutions that reduce logistical complexities and accelerate product delivery. The Optima labeler, set to be fully operational by mid-2025, automates key processes such as syringe labeling and plunger insertion, improving both speed and quality control.
“This expansion strengthens our role as a comprehensive partner, allowing clients to achieve faster time-to-market by managing every step of the PFS process,” said John Fowler, Chief Executive Officer at Pii. The company’s investment aims to meet the growing demand for prefilled syringes and support the increasing need for self-administered therapies in the pharmaceutical sector.
The Antares AVI system, expected to be client-ready by Q3 2025, further enhances Pii’s manufacturing capabilities by automating the inspection of critical parameters such as fill-level discrepancies and particle detection. This system supports stringent regulatory requirements by providing traceable inspection data, ensuring the safety and reliability of the products.
By integrating fill/finish, automated inspection, and labeling processes, Pharmaceutics International is positioning itself as a key player in the prefilled syringe manufacturing space. This investment is in line with Pii’s commitment to providing efficient, high-quality solutions to small and mid-sized pharmaceutical companies aiming to expedite their clinical trials and market entry.
Overview of outsourcing trends 
